Jie Li

Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study

Mefatinib, a novel second-generation epidermal growth factor (EGFR) tyrosine kinase inhibitor that has shown promising antitumor activity in targeting non-small cell lung cancer (NSCLC) with common and uncommon EGFR- activating mutations. In this phase III, randomized, double-bli...

Noninvasive Detection of MASH and Fibrotic Burden Using Ultrasound‐Derived LIID and LSM in MASLD: A Multicenter Study

ABSTRACT Background and Aims Metabolic dysfunction‐associated steatohepatitis (MASH), the progressive form of metabolic dysfunction‐associated steatotic liver disease (MASLD), is associated with adverse hepatic and cardiometabolic outcomes. The study aimed to validate a novel qua...